OncLive and Targeted Oncology: Drug yields long-lasting benefits to treat PEComa tumors
OncLive and Targeted Oncology covered research presented by the University of Cincinnati's Thomas Herzog that found patients with perivascular epithelioid sarcoma (PEComa) of gynecologic or peritoneal origin experienced rapid, durable responses when treated with the drug nab-sirolimus.
At the 2024 SGO Annual Meeting on Women's Cancer, Herzog presented results from a subgroup analysis of the phase 2 AMPECT trial. Nab-sirolimus is the first and only FDA-approved treatment for advanced PEComa.
"The median time to response was extremely fast, about 1.4 months, and the duration of response was a little over 36 months," Herzog, MD, a University of Cincinnati Cancer Center member, the Paul and Carolyn Flory Professor in Gynecologic Oncology in the UC College of Medicine and director of UC Health’s Gynecologic Cancer Disease Center, told Targeted Oncology. "It is important to remember these responses occur often rapidly, and they are quite durable."
Watch the Targeted Oncology video.
Featured photo at top of Thomas Herzog. Photo provided.
Related Stories
UC Speech & Hearing Clinic serves patients while acting as training site
September 30, 2026
The University of Cincinnati's Speech & Hearing Clinic provides graduate students in audiology and speech-language pathology with hands-on experience while delivering care to patients across the region. Located on the university's medical campus, the clinic serves patients of all ages and was recently featured on Spectrum News 1 Ohio.
UC economist warns of higher heating costs this winter
September 30, 2026
David Brasington explains why home heating will cost so much this winter and how to save money.
Former mistress of convicted pastor and former American Idol contestant likely won’t face criminal charges
September 30, 2026
Mark Godsey, a criminal law professor in the Donald P. Klekamp College of Law at the University of Cincinnati spoke with NBC News about a criminal case that has attracted national attention.